Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs RLX Technology Inc (RLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs RLX Technology Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $281.2 (market cap $39.89B), while RLX Technology Inc trades at $2 (market cap $2.38B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 16.8× RLX Technology Inc's market cap, and RLX Technology Inc pays a 5.13% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | RLX | |
|---|---|---|
Market Cap | $39.89B | $2.38B |
Sector | Health | Technology |
52-Week High | $491.22 | $2.73 |
52-Week Low | $278.09 | $1.79 |
Enterprise Value | $38.15B | $1.02B |
Dividend Yield | — | 5.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
RLX trades at $1.95, down 2.01% today, amid mixed technical signals with a neutral overall outlook. The company reported strong 2025 fundamentals with $3.62B revenue and $922M net income, though recent quarterly EPS results have missed expectations. Analyst coverage is limited to a single hold rating, while news highlights international expansion and a cash-rich, debt-free balance sheet.
The outlook is cautious due to earnings misses and a neutral technical stance, but the company's profitability, growth potential in the vaping industry, and solid financial health present a long-term opportunity. Key risks include regulatory pressures and competitive threats in the e-cigarette market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →
